A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors

PURPOSE: We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs. MATERIALS AND METHODS: This single-ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ji-Youn, Lee, Ki Hyeong, Kim, Sang-We, Min, Young Joo, Cho, Eunkyung, Lee, Youngjoo, Lee, Soo-Hyun, Kim, Hyae Young, Lee, Geon Kook, Nam, Byung Ho, Han, Hyesun, Jung, Jina, Lee, Jin Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266390/
https://www.ncbi.nlm.nih.gov/pubmed/27188206
http://dx.doi.org/10.4143/crt.2016.058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266390/
https://www.ncbi.nlm.nih.gov/pubmed/27188206
http://dx.doi.org/10.4143/crt.2016.058

Ejemplares similares